Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 오석중 | - |
dc.date.accessioned | 2022-03-14T08:03:02Z | - |
dc.date.available | 2022-03-14T08:03:02Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.citation | BRITISH JOURNAL OF HAEMATOLOGY, v. 189, no. 2, page. 303-312 | en_US |
dc.identifier.issn | 0007-1048 | - |
dc.identifier.issn | 1365-2141 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/bjh.16381 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/169050 | - |
dc.description.abstract | In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With >= 48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 <= 10% at three months, MMR and molecular response 4 center dot 5 (MR4 center dot 5) were achieved within 48 months by more radotinib-treated patients (300 mg: 84% and 52%, respectively; 400 mg: 74% and 44%, respectively) than imatinib-treated patients (71% and 44%, respectively). Estimated overall and progression-free survival rates at 48 months were not significantly different between imatinib (94% and 94%, respectively) and radotinib 300 mg (99% and 97%, respectively) or 400 mg (95% and 93%, respectively). The treatment failure rate was significantly higher with imatinib (19%) than with radotinib 300 mg (6%; P = 0 center dot 0197) or 400 mg (5%; P = 0 center dot 0072). Safety profiles were consistent with previous reports; most adverse events occurred within 12 months. Radotinib continues to demonstrate robust, deep molecular responses, suggesting that treatment-free remission may be attainable. | en_US |
dc.description.sponsorship | We thank the patients and investigators for their participation in the trial and the Korea Leukemia Bank for biomaterial banking and analysis (NRF-2013M3A9B8031236). This study was supported by funding from IL-YANG PHARM. Co., Ltd. All authors contributed to and approved the manuscript; writing and editorial assistance was provided by Rebecca Turner, PhD, of Ashfield Healthcare Communications, funded by IL-YANG PHARM. Co., Ltd. | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY | en_US |
dc.subject | chronic myeloid leukaemia | en_US |
dc.subject | imatinib | en_US |
dc.subject | newly diagnosed | en_US |
dc.subject | long-term data | en_US |
dc.subject | radotinib | en_US |
dc.title | Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1111/bjh.16381 | - |
dc.relation.journal | BRITISH JOURNAL OF HAEMATOLOGY | - |
dc.contributor.googleauthor | Do, Young Rok | - |
dc.contributor.googleauthor | Kwak, Jae-Yong | - |
dc.contributor.googleauthor | Kim, Jeong A. | - |
dc.contributor.googleauthor | Kim, Hyeoung Joon | - |
dc.contributor.googleauthor | Chung, Joo Seop | - |
dc.contributor.googleauthor | Shin, Ho-Jin | - |
dc.contributor.googleauthor | Kim, Sung-Hyun | - |
dc.contributor.googleauthor | Bunworasate, Udomsak | - |
dc.contributor.googleauthor | Choi, Chul Won | - |
dc.contributor.googleauthor | Oh, Suk Joong | - |
dc.relation.code | 2020045969 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | beatl51 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.